Dipeptidyl peptidase inhibitors
By designing new DPP-IV inhibitor compounds, the problems of insufficient stability and selectivity of existing DPP-IV inhibitors have been solved, and effective inhibition of DPP-IV and effective treatment of various diseases have been achieved.
CN102134230AInactive Publication Date: 2011-07-27TAKEDA PHARMA CO LTD
11 Cites 5 Cited by
Patent Information
- Application Number
- CN201110006009.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2004-11-18
- Filing Date
- 2004-12-15
- Publication Date
- 2011-07-27
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Technical Problem
Existing DPP-IV inhibitors have stability, selectivity and toxicity problems, are difficult to effectively inhibit DPP-IV activity, and have shortcomings in pharmacodynamics.
Method used
A new class of DPP-IV inhibitor compounds is provided. Through specific chemical structure design, it can effectively inhibit DPP-IV activity, has good stability and selectivity, and is suitable for the treatment of various diseases.
Benefits of technology
It achieves effective inhibition of DPP-IV, improves the stability and selectivity of the drug, and enhances the therapeutic effect on a variety of diseases, including the treatment of diabetes, immunosuppression, and neurological diseases.
✦ Generated by Eureka AI based on patent content.
Abstract
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising Formula (I): ##STR1## wherein M is N or CR4; Q1 and Q2 are each independently selected from the group consisting of CO, SO, SO2, and C=NR9; and each R1, R2, R3, R4 and R9 are as defined herein.
Need to check novelty before this filing date? Find Prior Art
